$72.40
0.00%
Nasdaq, Oct 02, 04:14 pm EDT. Closed.

Bio-Techne Corporation Target price 2026 - Analyst rating & recommendation

Bio-Techne Corporation Classifications & Recommendation

Buy
32%
Hold
68%

Bio-Techne Corporation Price Target

Target Price $74.46
Price $72.40
Potential
Number of Estimates 16
16 Analysts have issued a price target Bio-Techne Corporation 2027 . The average Bio-Techne Corporation target price is $74.46. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 22 analysts: 7 Analysts recommend Bio-Techne Corporation to buy, 15 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Bio-Techne Corporation stock has an average upside potential 2027 of . Most analysts recommend the Bio-Techne Corporation stock at Hold.

Sales and Margin forecast 2027, 2028 to 2030

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Jun '26 2027
Estimates
Revenue Billion $ 1.22 1.29
0.38% 6.42%
EBITDA Margin 24.98% 35.78%
2.68% 43.26%
Net Margin 14.97% 25.08%
148.81% 67.58%

16 Analysts have issued a sales forecast Bio-Techne Corporation 2027 . The average Bio-Techne Corporation sales estimate is

$1.3b
unlock
. This is
6.42% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.4b 11.52%
unlock
, the lowest is
$1.2b 0.82%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 $1.2b 0.38%
2027
$1.3b 6.42%
unlock
2028
$1.4b 9.82%
unlock
2029
$1.5b 8.87%
unlock
2030
$1.6b 5.95%
unlock

13 Analysts have issued an Bio-Techne Corporation EBITDA forecast 2027. The average Bio-Techne Corporation EBITDA estimate is

$463m
unlock
. This is
20.64% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$546m 42.42%
unlock
, the lowest is
$410m 6.81%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 $303m 2.29%
2027
$463m 52.47%
unlock
2028
$520m 12.36%
unlock
2029
$570m 9.65%
unlock
2030
$599m 5.04%
unlock

EBITDA Margin

2026 24.98% 2.68%
2027
35.78% 43.26%
unlock
2028
36.61% 2.32%
unlock
2029
36.87% 0.71%
unlock
2030
36.56% 0.84%
unlock

18 Bio-Techne Corporation Analysts have issued a net profit forecast 2027. The average Bio-Techne Corporation net profit estimate is

$324m
unlock
. This is
78.33% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$352m 93.78%
unlock
, the lowest is
$278m 53.10%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 $182m 147.87%
2027
$324m 78.35%
unlock
2028
$367m 13.19%
unlock
2029
$418m 13.75%
unlock
2030
$425m 1.81%
unlock

Net Margin

2026 14.97% 148.81%
2027
25.08% 67.58%
unlock
2028
25.85% 3.07%
unlock
2029
27.01% 4.49%
unlock
2030
25.95% 3.92%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2030

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Jun '26 2027
Estimates
Earnings Per Share $ 1.16 2.08
152.17% 79.31%
P/E 34.85
EV/Sales 8.73

18 Analysts have issued a Bio-Techne Corporation forecast for earnings per share. The average Bio-Techne Corporation EPS is

$2.08
unlock
. This is
79.31% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
$2.26 94.83%
unlock
, the lowest is
$1.78 53.45%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 $1.16 152.17%
2027
$2.08 79.31%
unlock
2028
$2.35 12.98%
unlock
2029
$2.67 13.62%
unlock
2030
$2.72 1.87%
unlock

P/E ratio

Current 62.41 45.83%
2027
34.85 44.16%
unlock
2028
30.79 11.65%
unlock
2029
27.07 12.08%
unlock
2030
26.58 1.81%
unlock

Based on analysts' sales estimates for 2027, the Bio-Techne Corporation stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 9.29 37.43%
2027
8.73 6.02%
unlock
2028
7.95 8.94%
unlock
2029
7.30 8.15%
unlock
2030
6.89 5.62%
unlock

P/S ratio

Current 9.34 41.30%
2027
8.78 6.03%
unlock
2028
8.00 8.94%
unlock
2029
7.34 8.15%
unlock
2030
6.93 5.62%
unlock

Current Bio-Techne Corporation Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wells Fargo
Locked
➜
Locked
Locked Aug 13 2026
RBC Capital
Locked
➜
Locked
Locked Jul 09 2026
Benchmark
Locked
➜
Locked
Locked Jun 30 2026
TD Cowen
Locked
➜
Locked
Locked Jun 30 2026
Citigroup
Locked
➜
Locked
Locked Jun 29 2026
Stephens & Co.
Locked
➜
Locked
Locked Jun 26 2026
Baird
Locked
➜
Locked
Locked Jun 26 2026
Analyst Rating Date
Locked
Wells Fargo:
Locked
➜
Locked
Aug 13 2026
Locked
RBC Capital:
Locked
➜
Locked
Jul 09 2026
Locked
Benchmark:
Locked
➜
Locked
Jun 30 2026
Locked
TD Cowen:
Locked
➜
Locked
Jun 30 2026
Locked
Citigroup:
Locked
➜
Locked
Jun 29 2026
Locked
Stephens & Co.:
Locked
➜
Locked
Jun 26 2026
Locked
Baird:
Locked
➜
Locked
Jun 26 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today